Core Insights - The collaboration between Zedman Pharmaceuticals and JD Health aims to provide affordable access to innovative treatments for patients with atopic dermatitis through a promotional campaign during JD's 11.11 shopping festival [1][2] - Zedman’s product, Zeli Mei cream, is the first aromatic receptor innovation drug approved for treating eczema in children over 2 years old and adults, demonstrating a high efficacy rate of 83.9% in clinical trials for children aged 7-11 [1] - The partnership emphasizes a comprehensive health management system that includes prevention, diagnosis, and treatment, enhancing JD Health's supply chain capabilities in dermatological products [1] Summary by Sections Collaboration Details - Zedman Pharmaceuticals and JD Health launched a "Caring for Patients" initiative, allowing patients to purchase Zeli Mei cream for only 10 yuan after receiving a 350 yuan coupon [1] - This initiative is part of a broader strategy to ensure patients have access to innovative treatment options through compliant drug supply channels [1] Product Information - Zeli Mei cream is a non-hormonal treatment for eczema, recognized for its safety and effectiveness, with mild to moderate adverse reactions reported [1] - The product has achieved a dual breakthrough in providing rapid itch relief and long-term skin repair [1] Previous Initiatives - In September, JD Health and Zedman initiated the "Health Escort, Safe Transition" campaign to support seasonal health issues, further expanding their collaboration in the dermatological sector [1] - The partnership leverages JD Health's full-chain capabilities in medical services, testing, diagnosis, and medication [1] Safety and Compliance - Zedman Pharmaceuticals values JD Health's strict identity verification, prescription review, and drug traceability systems, which ensure patient safety and respect for drug distribution regulations [2]

据介绍，芳香烃受体(aryl hydrocarbons receptor，简称AhR)是介导环境因素与免疫系统细胞成分相互作 用的一种细胞信号传导体。皮肤细胞表达AhR受体，AhR通路参与维持皮肤稳态和缓解皮肤炎症。在芳 香烃受体调节剂中，上海泽德曼医药科技有限公司于2024年11月上市的泽立美本维莫德乳膏，在我国已 获批用于治疗2岁及以上儿童和成人轻中度特应性皮炎。 据悉，该《共识》由北京大学人民医院皮肤科张建中教授担任通信作者，联合国内32位皮肤科、变态反 应科及儿科学专家历经4轮论证，参考国内外65项研究证据，首次建立符合中国患者特征的规范化外用 药诊疗体系。 本报讯(记者金婉霞)日前，《特应性皮炎外用治疗与管理专家共识(2025版)》(以下简称《共识》)在《中 华皮肤科杂志》刊发，首次对原研创新药物泽立美本维莫德乳膏作出规范化临床应用指导。 《共识》指出，特应性皮炎在我国儿童群体中患病率达10%—15%。针对占比达三分之二的轻中度患 者，专家团队基于中国人群研究数据，将芳香烃受体调节剂泽立美本维莫德乳膏列为重要治疗选择。 ...

Core Insights - The "Expert Consensus on the Treatment and Management of Atopic Dermatitis (2025 Edition)" has been published, providing standardized clinical application guidance for the innovative drug, Zeli Mei Ben Wei Mo De Ointment [1][2] - Atopic dermatitis (AD) has a prevalence rate of 10%-15% among children in China, making it the leading non-fatal skin disease burden [1] - The consensus emphasizes the importance of Zeli Mei Ben Wei Mo De Ointment as a treatment option for the two-thirds of patients with mild to moderate AD, based on research data from the Chinese population [1][2] Treatment Mechanism - Zeli Mei Ben Wei Mo De Ointment works by inhibiting type 2 inflammatory cytokines and repairing the skin barrier, specifically targeting IL-4/IL-13 induced tight junction damage [2] - Clinical trials indicate that the ointment can reduce and eliminate skin lesions while alleviating itching, with most adverse reactions being mild to moderate [2] Treatment Guidelines - The consensus provides clear guidelines for treating special areas and populations, recommending the use of moderately potent topical medications in sensitive areas to avoid the risk of skin atrophy from long-term corticosteroid use [2] - The dual mechanism of Zeli Mei Ben Wei Mo De Ointment offers unique advantages in addressing the inflammatory responses and barrier defects commonly seen in AD patients in China, particularly for children and those contraindicated for steroids [2] - The publication of the consensus aims to guide medical institutions in standardizing the selection of topical medications for AD, promoting the standardization of AD diagnosis and treatment in China [2]

Core Insights - The 82nd American Academy of Dermatology Annual Meeting showcased significant clinical research data on the efficacy of Zeli Mei Ben Wei Mo De cream for treating atopic dermatitis (AD) in the Chinese population, highlighting its rapid itch relief, long-lasting efficacy, and safety profile [1][6]. Research Core Findings - Rapid Itch Relief: Zeli Mei cream demonstrated significant itch relief starting from day one of treatment, with a notable improvement on day two, showing a -5.2% change in average PP-NRS on day one and -8.0% on day two compared to the placebo group [2]. - Long-term Efficacy Maintenance: A one-year study indicated a high no-recurrence rate of 70% after discontinuation of the cream, showcasing its long-term disease control capabilities [2][4]. Research Details - Study Design: The multi-center, confirmatory clinical study involved 272 patients aged 2 years and older with moderate to severe AD across over 30 locations in China, using a randomized, double-blind, placebo-controlled method [3]. - Baseline Characteristics: The majority of the study population (52.2%) were children aged 2-17 years, with an average body surface area (BSA) of approximately 15%, indicating a wide coverage of age groups and disease severity [3]. - Efficacy Data Analysis: After 8 weeks of treatment, the Zeli Mei group achieved EASI75 and IGA response rates of 54.4% and 46.2%, respectively, significantly higher than the placebo group, demonstrating its effectiveness in improving skin lesions and overall disease control [3]. Safety Analysis - Adverse Reactions Overview: Among 193 patients treated with Zeli Mei cream, common adverse reactions included folliculitis (5.7%), pain (3.1%), and pruritus (3.1%), all classified as mild to moderate, with no severe adverse events reported [5]. - Safety Conclusion: The safety profile of Zeli Mei cream is favorable, indicating its suitability for long-term use [5]. Expert Opinions and Industry Significance - Experts highlighted the promising results of Zeli Mei cream in rapid itch relief and long-term disease alleviation, with a low recurrence rate of 70%, marking a new chapter in non-hormonal treatment for AD [6][7]. - The CEO of Zedman emphasized the global potential of Zeli Mei cream and the company's commitment to innovative drug development, enhancing China's international standing in the field of innovative drug research [7].